Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02658357 · ClinicalTrials.gov registry record · Phase 2
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
A Phase 2 study of Schizophrenia and Schizoaffective Disorder, sponsored by Braeburn Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT02658357: Completed Phase 2 study of Schizophrenia and Schizoaffective Disorder, sponsored by Braeburn Pharmaceuticals.
NCT02658357 is a Phase 2 study of Schizophrenia and Schizoaffective Disorder that has completed, run by Braeburn Pharmaceuticals. The registered enrollment target is 66 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02658357, a Phase 2 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Braeburn Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three, 300 mg Risperidone Implants.
Conditions Studied
Interventions
- DRUG Risperidone Implant
Study Locations (1)
Florida
- Segal Institute for Clinical Research 1201 North 37th Avenue - Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
What the finished NCT02658357 record still lists
NCT02658357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Risperidone Implant is the first listed.
NCT02658357 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02658357 about?
NCT02658357 is a clinical study titled "Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant". The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three, 300 mg Ri...
What is the current status of trial NCT02658357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2015-10. Estimated completion is 2017-08.
What conditions does trial NCT02658357 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT02658357?
The interventions under investigation include: Risperidone Implant (DRUG).
Who is sponsoring clinical trial NCT02658357?
This trial is sponsored by Braeburn Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02658357 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02658357's enrollment target sits among peer trials
66 183rd of 315 higher than 133 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia